You are here: Welcome » Pharmaceutical Industry » Controversies Surrounding the Pharmaceutical Industry

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
pharmaceutical_industry:controversies [2022/01/08 15:02]
robert [Dangerous Medication] 		pharmaceutical_industry:controversies [2022/03/28 10:31] (current)
mathew
Line 60: Line 60:
 === Study 329 === === Study 329 ===
 "In the early 2000s, based on Study 329, GlaxoSmithKline (GSK) marketed Paxil (paroxetine) as safe and effective for children and adolescents when company executives were aware that a number of studies (all but Study 329 unpublished) had shown that the drug was no better than placebo and caused thought disturbance and suicidal behavior in some youngsters."((https://study329.org/ | Restoring Study 329: Scientific Integrity Through Data Based Medicine)) "In the early 2000s, based on Study 329, GlaxoSmithKline (GSK) marketed Paxil (paroxetine) as safe and effective for children and adolescents when company executives were aware that a number of studies (all but Study 329 unpublished) had shown that the drug was no better than placebo and caused thought disturbance and suicidal behavior in some youngsters."((https://study329.org/ | Restoring Study 329: Scientific Integrity Through Data Based Medicine))
 +
 +[[https://pubmed.ncbi.nlm.nih.gov/23521369/|Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review]]
 +
 +[[https://pubmed.ncbi.nlm.nih.gov/12533125/|Scope and impact of financial conflicts of interest in biomedical research: a systematic review]]
 +
 +[[https://www.nejm.org/doi/full/10.1056/NEJM200005183422024|Uneasy alliance - clinical investigators and the pharmaceutical industry]]
 +
 +[[https://www.nejm.org/doi/10.1056/NEJMed010093?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov|Sponsorship, Authorship, and Accountability]]
 +
 +
 +[[https://www.bmj.com/content/bmj/356/bmj.i6770.full.pdf|Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study]]
 +
  
 ===== Medical Provider Capture ===== ===== Medical Provider Capture =====
Line 68: Line 80:
  
 ===== Terrorism Funding Claims ===== ===== Terrorism Funding Claims =====
-In January, 2022, a U.S. appeals court revived a lawsuit against several pharmaceutical companies including [[Pfizer]] and [[AstraZeneca]] over allegations of contracts in [[Iraq]] that funded terrorism that resulted in the deaths of Americans during the Iraq War.((Jan 4, 2022 | Mike Scarcella | [[Reuters]] | [[https://news.yahoo.com/u-court-revives-lawsuit-against-193221732.html|U.S. court revives lawsuit against Pfizer, others on Iraq terrorism funding claims]]))+In January, 2022, a U.S. appeals court revived a lawsuit against several pharmaceutical companies including [[Pfizer]] and [[AstraZeneca]] over allegations of contracts in [[Iraq]] that funded terrorism that resulted in the deaths of Americans during the Iraq War.((January 4, 2022 | Mike Scarcella | [[Reuters]] | [[https://news.yahoo.com/u-court-revives-lawsuit-against-193221732.html|U.S. court revives lawsuit against Pfizer, others on Iraq terrorism funding claims]]))((January 6, 2022 | Kevin Dunleavy | [[Fierce Pharma]] | [[https://www.fiercepharma.com/pharma/appeals-court-revives-lawsuit-against-pfizer-roche-astrazeneca-and-johnson-johnson-claims|Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming they funded terrorism in Iraq]]))
  
Back to top